Publication at Second Faculty of Medicine |
2012
Abstract
Sitagliptin is the first inhibitor of DPP 4, which has been put on the market. Past experience confirms the good clinical efficacy and safety.
Sitagliptin is indicated in the treatment of type 2 diabetes type klinikcých in a wide range of situations, most notably its effect occurs in combination with metformin.